A phase I study of sequential vinorelbine followed by paclitaxel Academic Article Article uri icon

Overview

MeSH Major

  • Clinical Trials as Topic
  • Neoplasms
  • Patient Selection
  • Research Subjects

abstract

  • Sequential administration of these two agents demonstrates activity in breast cancer patients. Phase II dosing on this schedule should be vinorelbine 13 mg/m2/day x 3 and paclitaxel 175 mg/m2. With proper selection of patients, concern about neurologic toxicity should not impede future trials of vinorelbine with paclitaxel.

publication date

  • August 15, 1999

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1023/A:1008351915582

PubMed ID

  • 10470436

Additional Document Info

start page

  • 861

end page

  • 3

volume

  • 10

number

  • 7